» Articles » PMID: 17008540

Beyond HLA: the Significance of Genomic Variation for Allogeneic Hematopoietic Stem Cell Transplantation

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2006 Sep 30
PMID 17008540
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

The last 2 years have seen much excitement in the field of genetics with the identification of a formerly unappreciated level of "structural variation" within the normal human genome. Genetic structural variants include deletions, duplications, and inversions in addition to the recently discovered, copy number variants. Single nucleotide polymorphisms are the most extensively evaluated variant within the genome to date. Combining our knowledge from these studies with our rapidly accumulating understanding of structural variants, it is apparent that the extent of genetic dissimilarity between any 2 individuals is considerable and much greater than that which was previously recognized. Clearly, this more diverse view of the genome has significant implications for allogeneic hematopoietic stem cell transplantation, not least in the generation of transplant antigens but also in terms of individual susceptibility to transplant-related toxicities. With advances in DNA sequencing technology we now have the capacity to perform genome-wide analysis in a high throughput fashion, permitting a detailed genetic analysis of patient and donor prior to transplantation. Understanding the significance of this additional genetic information and applying it in a clinically meaningful way will be one of the challenges faced by transplant clinicians in the future.

Citing Articles

Shared graft-versus-leukemia minor histocompatibility antigens in DISCOVeRY-BMT.

Olsen K, Jadi O, Dexheimer S, Bortone D, Vensko S, Bennett S Blood Adv. 2022; 7(9):1635-1649.

PMID: 36477467 PMC: 10182302. DOI: 10.1182/bloodadvances.2022008863.


Class I/Class II HLA Evolutionary Divergence Ratio Is an Independent Marker Associated With Disease-Free and Overall Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.

Daull A, Dubois V, Labussiere-Wallet H, Venet F, Barraco F, Ducastelle-Lepretre S Front Immunol. 2022; 13:841470.

PMID: 35309346 PMC: 8931406. DOI: 10.3389/fimmu.2022.841470.


A Model of Minor Histocompatibility Antigens in Allogeneic Hematopoietic Cell Transplantation.

Martin P, Levine D, Storer B, Zheng X, Jain D, Heavner B Front Immunol. 2021; 12():782152.

PMID: 34868058 PMC: 8636906. DOI: 10.3389/fimmu.2021.782152.


Association of recipient and donor interleukin 6 polymorphisms 174 and 597 with outcome after allogeneic hematopoietic stem cell transplantation in children.

Wetzel L, Wittig S, Gruhn B J Cancer Res Clin Oncol. 2021; 148(1):255-265.

PMID: 34120222 PMC: 8752556. DOI: 10.1007/s00432-021-03677-5.


Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation.

Story C, Wang T, Bhatt V, Battiwalla M, Badawy S, Kamoun M Transplant Cell Ther. 2021; 27(7):591-599.

PMID: 33882342 PMC: 8343993. DOI: 10.1016/j.jtct.2021.04.003.